Research Alliance V, the fifth blank check company formed by RA Capital targeting healthcare, life sciences, and healthtech, filed on Monday with the SEC to raise up to $62 million in an initial public offering.
The company plans to raise $62 million by offering 6.2 million shares at $10. Unlike most SPACs, Research Alliance V does not plan to offer units with warrants or rights attached.
Research Alliance V is led by CEO and Director Matthew Hammond, a Partner on the Investment Team at RA Capital Management. Hammond has experience with other SPACs and concurrently serves as CEO of Research Alliance III (Nasdaq: RACC), which has a pending combination with OHB Pediatrics, and Research Alliance IV (Nasdaq: RACD). He previously served as CFO of Research Alliance I through its 2021 merger with POINT Biopharma (formerly Nasdaq: PNT), which Eli Lilly acquired for about $1.4 billion in 2023. He is joined by CFO Fran Adams, a Partner at van den Boom and Associates, who also serves as CFO of Research Alliance III and IV.
The SPAC plans to target businesses in the healthcare sector, focusing on drug development and commercialization, diagnostics, and healthcare technology and services. Research Alliance V’s sponsor is owned by funds advised by RA Capital Management.
The New York, NY-based company was founded in 2026. It plans to list on the Nasdaq under the symbol RACV. Leerink Partners is the sole bookrunner on the deal.
